Honda S et al. – RASSF1A methylation may be a promising molecular-genetic marker to predict the treatment outcome and may serve to stratify pts for clinical trials Methods
Study of methylation status of 13 candidate tumor suppressor genes in 20 hepatoblastoma tumors by conventional methylation-specific PCR (MSP); subsequent review of hypermethylation in 3 of 13 genes
Analysis of methylation status of 3 genes (RASSF1A, SOCS1, CASP8) in 97 tumors
Univariate analysis showed only RASSF1A methylation status but not the other 2 genes predicted outcome; independent prognostic factors: RASSF1A methylation, CTNNB1 mutation, and other clinicopathological variables
Multivariate analysis showed weak contribution of RASSF1A methylation to overall survival; independent prognostic factors: RASSF1A methylation and disease stage but not CTNNB1 mutation
Of 97 tumors, RASSF1A methylation in 44.3%; CTNNB1 mutation in 67%
In survival analysis of 33 stage 3B or 4 pts, overall survival was better for pts with unmethylated vs methylated tumor
See all
